Sanofi (SNY) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$43.18
Price Target
$50.00
Target Range
$50.00 — $50.00
Analyst Rating
Buy
Forward P/E10.3x
Trailing P/E18.1x
Forward PEG—
Implied Growth+31.5%
Median Target$50.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$50
+15.8%
Consensus
$50
+15.8%
Bull Case
$50
+15.8%
Valuation Model TargetsConfidence: 58/100
Bear$25
Base$68
Bull$139
SNY Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Sanofi (SNY) has a Wall Street consensus price target of $50.00, based on estimates from 27 covering analysts. With the stock currently trading at $43.18, this represents a potential upside of +15.8%. The company has a market capitalization of $104.28B.
Analyst price targets range from a low of $50.00 to a high of $50.00, representing a 0% spread in expectations. The median target of $50.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SNY trades at a trailing P/E of 18.1x and forward P/E of 10.3x. Analysts expect EPS to grow +31.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $67.88, with bear and bull scenarios of $24.88 and $138.98 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+11.5%
Avg Forward P/E14.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVONovo Nordisk A/S | $203.5B | $45.79 | $47.00 | +2.6% | Buy | 2.1x | 39 |
 AZNAstraZeneca PLC | $283.0B | $182.52 | $211.00 | +15.6% | Buy | 17.7x | 41 |
 NVSNovartis AG | $277.4B | $145.39 | $141.00 | -3.0% | Hold | 16.6x | 25 |
 GSKGSK plc | $101.6B | $50.50 | $52.45 | +3.9% | Hold | 10.4x | 29 |
 PFEPfizer Inc. | $150.6B | $26.48 | $27.27 | +3.0% | Hold | 8.9x | 39 |
 MRKMerck & Co., Inc. | $277.3B | $112.29 | $129.31 | +15.2% | Buy | 21.9x | 37 |
 LLYEli Lilly and Company | $921.2B | $974.96 | $1258.47 | +29.1% | Buy | 28.2x | 45 |
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
 BMYBristol-Myers Squibb Company | $114.8B | $56.25 | $62.00 | +10.2% | Hold | 8.9x | 41 |
 JNJJohnson & Johnson | $536.2B | $222.51 | $249.27 | +12.0% | Buy | 19.2x | 40 |
Upside Potential Comparison
LLYABBVAZNMRKJNJBMYGSKPFEFull SNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNY — Frequently Asked Questions
Quick answers to the most common questions about buying SNY stock.
What is the SNY stock price target for 2026?
Sanofi (SNY) has a consensus 12-month price target of $50, implying 15.8% upside from $43.18. The 27 analysts covering SNY see moderate appreciation potential.
Is SNY a buy, sell, or hold?
SNY has a consensus rating of "Buy" based on 27 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $50 implies 15.8% upside from current levels.
Is SNY stock overvalued or undervalued?
With a forward P/E of 10.257x, SNY trades at a relatively low valuation. The consensus target of $50 implies 15.8% appreciation, suggesting meaningful undervaluation.
How high can SNY stock go?
The most bullish Wall Street analyst has a price target of $50 for SNY, while the most conservative target is $50. The consensus of $50 represents the median expectation. Our quantitative valuation model projects a bull case target of $139 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover SNY stock?
SNY is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 11 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SNY stock forecast?
The 12-month SNY stock forecast based on 27 Wall Street analysts shows a consensus price target of $50, with estimates ranging from $50 (bear case) to $50 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $68, with bear/bull scenarios of $25/$139.
What is SNY's fair value based on fundamentals?
Our quantitative valuation model calculates SNY's fair value at $68 (base case), with a bear case of $25 and bull case of $139. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.
What is SNY's forward P/E ratio?
SNY trades at a forward P/E ratio of 10.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy SNY stock?
Wall Street analysts are optimistic on SNY, with a "Buy" consensus rating and $50 price target (15.8% upside). 14 of 27 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SNY price targets vary so much?
SNY analyst price targets range from $50 to $50, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50 consensus represents the middle ground. Our model's $25-$139 range provides an independent fundamental perspective.